CJC-1295: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, and no outcome is presented as a benefit that a reader should expect. The aim is narrower: to describe what published studies on CJC-1295 actually did, what they measured, and what they reported.

Module 1: What CJC-1295 Is and How It Has Been Studied

Definition and class

CJC-1295 belongs to the class of growth hormone-releasing hormone (GHRH) analogs. Its peptide backbone is derived from human growth hormone-releasing factor residues 1-29, the shortest fragment of native GHRH that retains full biological activity at the GHRH receptor. The defining modification is a reactive chemical group that allows the peptide to form a covalent bond with circulating albumin after administration, a strategy described in the foundational rat work that first characterised hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as a long-lasting GRF analog (Endocrinology, 2005).

Origin of the molecule

The 2005 rat study screened a series of hGRF(1-29)-albumin bioconjugates for their ability to activate the GRF receptor on the anterior pituitary and selected CJC-1295 from that series as the long-acting candidate (Endocrinology, 2005). Subsequent animal work moved into a genetic disease model: researchers administered CJC-1295 once daily to GHRH knockout mice and reported that growth was normalised in that model (American Journal of Physiology - Endocrinology and Metabolism, 2006).

Forms and naming confusion

A recurring point of confusion in the wider literature and in non-scientific sources is that the name "CJC-1295" has been applied both to the albumin-binding bioconjugate described above and, informally, to a non-binding modified GRF(1-29) peptide. Analytical chemistry publications have had to confront this directly. One report described the identification of CJC-1295 in an unknown pharmaceutical preparation, a case that illustrates how material circulating outside regulated supply chains has required laboratory characterisation to establish what it actually contained (Drug Testing and Analysis, 2010).

The study base at a glance

Limits of the evidence in Module 1

The published base is small and heavily weighted toward short pharmacology studies in healthy volunteers and toward analytical detection methods developed for anti-doping purposes. There is no large, long-duration clinical programme in the verified literature, no head-to-head comparison with approved growth hormone products, and no study population defined by a disease indication in humans.

Module 2: Mechanism as Described in the Literature

Receptor-level description

The mechanism described across these papers is indirect: CJC-1295 is reported to act at the GHRH (GRF) receptor on somatotroph cells of the anterior pituitary rather than supplying growth hormone itself. The rat bioconjugate study reported that hGRF(1-29)-albumin bioconjugates activated the GRF receptor on the anterior pituitary (Endocrinology, 2005). Downstream of that receptor, pituitary release of endogenous growth hormone drives hepatic and peripheral production of insulin-like growth factor I (IGF-I), which is why IGF-I appears as a principal endpoint in the human work.

Why the albumin bond matters

Native GHRH and the unmodified 1-29 fragment are cleared rapidly. The design logic described in the 2005 rat study was that covalent attachment to albumin would prolong exposure and produce a long-lasting GRF analog (Endocrinology, 2005). Human work then asked whether prolonged receptor stimulation translated into prolonged hormone output, and the 2006 clinical study reported prolonged stimulation of GH and IGF-I secretion in healthy adults (Journal of Clinical Endocrinology and Metabolism, 2006).

The pulsatility question

A mechanistically important question is whether continuous stimulation flattens the normal pulsatile pattern of GH release, since pulsatility is thought to matter physiologically. A dedicated clinical study addressed this and reported that pulsatile secretion of growth hormone persisted during continuous stimulation by CJC-1295 (Journal of Clinical Endocrinology and Metabolism, 2006). That finding is descriptive of hormone dynamics; it does not establish any clinical consequence.

Limits of the evidence in Module 2

Mechanism here is inferred from hormone measurements and receptor pharmacology, not from tissue-level outcomes in humans. None of the verified papers traced the pathway through to functional endpoints such as muscle mass, bone density, body composition or sleep architecture in people. Mechanistic plausibility is not the same as demonstrated effect.

Module 3: Reported Outcomes by Study

Preclinical outcomes

In the GHRH knockout mouse — an animal that cannot produce its own GHRH and therefore grows poorly — researchers reported that once-daily administration of CJC-1295 normalised growth in that model (American Journal of Physiology - Endocrinology and Metabolism, 2006). The endpoint was growth in a genetic deficiency model, not enhancement in a normal animal, and that distinction is frequently lost when the study is summarised elsewhere.

Clinical hormone endpoints

The principal human study in healthy adults reported prolonged stimulation of growth hormone and IGF-I secretion following CJC-1295 administration (Journal of Clinical Endocrinology and Metabolism, 2006). A companion clinical report examined the temporal pattern rather than the magnitude and reported persistence of GH pulsatility under continuous stimulation (Journal of Clinical Endocrinology and Metabolism, 2006). Both endpoints are biochemical.

Serum protein profiling

A later analysis in normal adult subjects asked what activation of the GH/IGF-1 axis by CJC-1295 did to the broader serum proteome, and the study reported serum protein profile changes accompanying that activation (Growth Hormone & IGF Research, 2009). Biomarker shifts of this kind are exploratory; they describe what moved in the blood, not whether anything changed in how subjects felt or functioned.

Non-clinical observational accounts

A qualitative study took a different approach entirely, using netnography — structured observation of online communities — to describe female use of CJC-1295 outside medical supervision, and the authors reported on the practices and narratives surrounding that use (Substance Use & Misuse, 2016). This is sociological documentation of behaviour, not evidence of efficacy or safety.

Limits of the evidence in Module 3

No verified study reported an outcome in body composition, strength, recovery, wound healing, sleep quality or ageing-related endpoints in humans. Every human outcome in this list is a laboratory measurement. Claims of physical or aesthetic benefit are not supported by these papers, and the products discussed in online communities were not analytically verified as matching what clinical studies administered.

Module 4: CJC-1295 Side Effects: What Studies Report

What the clinical papers characterise

The healthy-adult clinical work that reported prolonged GH and IGF-I secretion also constituted the safety-relevant human exposure in the verified set, and the overall clinical record on CJC-1295 in these papers is limited to small numbers of healthy subjects observed over short periods (Journal of Clinical Endocrinology and Metabolism, 2006). A second clinical report in the same population examined GH secretion patterns during continuous stimulation and similarly involved short-term observation in healthy volunteers (Journal of Clinical Endocrinology and Metabolism, 2006). Readers seeking a tabulated adverse-event list should note that these abstracts centre on hormone endpoints rather than on tolerability statistics, and no adverse-event frequencies can be quoted from them here without inventing numbers.

Biomarker changes as a safety-adjacent signal

The serum proteomics study is the closest thing in this set to a systematic look at off-target biological change: researchers reported that activation of the GH/IGF-1 axis by CJC-1295 was accompanied by changes in the serum protein profile of normal adult subjects (Growth Hormone & IGF Research, 2009). Whether those shifts carry any clinical meaning — favourable, neutral or harmful — was not established by that study.

Risks arising from unregulated material

A distinct category of documented risk concerns product identity rather than pharmacology. Analytical chemists reported identifying CJC-1295 within an unknown pharmaceutical preparation, a scenario in which the contents of a vial were not established until laboratory analysis was performed (Drug Testing and Analysis, 2010). The netnographic study documented use occurring outside clinical oversight, where composition, purity and dosing are unverified (Substance Use & Misuse, 2016). Uncertainty about what a preparation contains is itself a hazard the literature has described.

Limits of the evidence in Module 4

There is no long-term human safety dataset for CJC-1295 in the verified literature — no multi-year follow-up, no cancer surveillance, no glucose or insulin-sensitivity outcome study, no pregnancy or paediatric data. Because GHRH analogs raise IGF-I, questions about sustained IGF-I elevation are biologically reasonable, but none of these papers answered them. Absence of reported harm in small short studies is not evidence of long-term safety.

Module 5: Pharmacokinetics Where Data Exist

The half-life question

The pharmacokinetic story is the reason CJC-1295 exists as a distinct molecule. The rat study that characterised hGRF(1-29)-albumin bioconjugates identified CJC-1295 specifically as a long-lasting GRF analog, meaning duration of action rather than potency was the selection criterion (Endocrinology, 2005). In humans, the corresponding pharmacodynamic observation was prolonged stimulation of GH and IGF-I secretion in healthy adults (Journal of Clinical Endocrinology and Metabolism, 2006).

Dosing interval in animals

The knockout-mouse study used a once-daily administration schedule and reported growth normalisation on that interval (American Journal of Physiology - Endocrinology and Metabolism, 2006). That is an animal dosing interval reported in a disease model; it is not a human regimen and is described here only as a study design detail.

Detectability as an indirect PK measure

Anti-doping science has generated some of the most practical information on how long CJC-1295 and related compounds remain measurable. Researchers developed an LC-MS/MS method for confirming CJC-1295 abuse in equine plasma samples (Drug Testing and Analysis, 2019), and a separate group described an immuno-polymerase chain reaction screen for detecting CJC-1295 and other GHRH analogs in equine plasma (Drug Testing and Analysis, 2019). Both were built because the compound persists long enough in plasma to be worth screening for in regulated animal sport.

Limits of the evidence in Module 5

No numeric human half-life, clearance value, bioavailability figure or exposure curve can be quoted from the verified abstracts, so none is given. Equine detection data do not transfer to human pharmacokinetics. Route-of-administration comparisons and the influence of body weight, age, sex, renal function or hepatic function on exposure were not addressed in this set.

Module 6: Regulatory Status Stated Factually

Approval status

CJC-1295 is not an approved drug product in the United States or the European Union. There is no marketing authorisation, no approved label, no indication and no regulator-reviewed prescribing information. Material bearing the name is typically designated research-use-only (RUO), a labelling category that signals the substance is intended for laboratory investigation and has not been evaluated for human administration.

Compounding

In the United States, compounding pharmacies operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and the bulk drug substances they may use are constrained by statutory lists and FDA nomination processes. Peptides that lack an approved product and that are not on the applicable bulk substance lists fall outside what compounders may lawfully prepare. The FDA has separately categorised a number of peptide substances by the agency's assessment of their safety risks for compounding. This page is for educational purposes only and is not medical advice, nor is it legal advice; regulatory status changes and licensed professionals should be consulted on any specific question.

Sport and animal-sport regulation

GHRH analogs sit within prohibited categories in human and equine sport, which is precisely why detection chemistry exists. Published methods for confirming CJC-1295 in equine plasma by LC-MS/MS (Drug Testing and Analysis, 2019) and for screening CJC-1295 and other GHRH analogs by immuno-PCR (Drug Testing and Analysis, 2019) were developed in a racing anti-doping context.

Grey-market identification

The forensic identification of CJC-1295 in an unknown pharmaceutical preparation documented that material of uncertain provenance has circulated and required analytical characterisation (Drug Testing and Analysis, 2010), and the netnographic study documented a community of women using the compound outside medical channels (Substance Use & Misuse, 2016).

Limits of the evidence in Module 6

Regulatory categories vary by country and change over time. Nothing in this module describes availability, and none of the cited papers evaluated the legality of any particular activity.

Closing: What the Studies Did Not Test

Setting out the gaps is as informative as listing the findings. Across the verified literature, the following were not tested:

• Combination with ipamorelin or any growth hormone secretagogue. No verified study administered CJC-1295 together with a ghrelin-receptor agonist, so combined effects, combined tolerability and any interaction are undocumented in this evidence base.
• Functional human outcomes. Muscle mass, fat mass, strength, injury recovery, sleep, cognition, skin and longevity endpoints were not endpoints in any cited human study.
• Long-term administration. No multi-year exposure, no cancer or mortality surveillance, no metabolic follow-up.
• Special populations. Older adults with age-related GH decline, people with growth hormone deficiency, children, pregnant people and those with organ impairment were not studied in this set.
• Comparative effectiveness. No comparison against recombinant growth hormone or other GHRH analogs.
• Product equivalence. Whether material sold under the CJC-1295 name matches the bioconjugate studied clinically was not established, and the one analytical case report on an unknown preparation underlines the question rather than answering it (Drug Testing and Analysis, 2010).

What remains, fairly stated, is a molecule with a coherent design rationale demonstrated in rats (Endocrinology, 2005), a corrective effect on growth in a GHRH-deficient mouse model (American Journal of Physiology - Endocrinology and Metabolism, 2006), and reproducible hormone-axis activation in small groups of healthy adults (Journal of Clinical Endocrinology and Metabolism, 2006). Everything beyond that is extrapolation.

References

• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Endocrinology, 2005)
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (American Journal of Physiology. Endocrinology and Metabolism, 2006)
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis, 2010)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma (Drug Testing and Analysis, 2019)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)